广泛耐药结核患者使用贝达喹啉的群体影响:耐药担忧是否合理?
本文为个人观点文章,讨论广泛耐药结核患者使用贝达喹啉的耐药担忧。作者基于三点论证支持增加该类患者贝达喹啉可及性:含贝达喹啉方案可能减少社区传播;不提供或因耐药无效面临等效结局;耐药突变限于单染色体不显著增加非XDR患者耐药风险。
要点
- 广泛耐药结核患者死亡率极高,对贝达喹啉需求最大。
- 耐药担忧不应阻碍广泛耐药结核患者使用贝达喹啉。
- 贝达喹啉耐药突变在单染色体,不显著增加非XDR菌株耐药风险。
核心结论
- 耐药担忧不应阻碍广泛耐药结核患者使用贝达喹啉,应增加该人群药物可及性。
研究设计与样本
- 个人观点文章,未报告系统检索范围或样本量。
主要发现
- 含贝达喹啉的药物组合可能减少广泛耐药结核在社区的传播。
- 在新型联合方案可用前,政策不提供贝达喹啉或因耐药无效,广泛耐药患者及其接触者结局等效。
- 贝达喹啉及其他抗结核药物耐药由单条细菌染色体突变引起,广泛耐药患者使用贝达喹啉不会显著增加药物敏感或耐多药(非XDR)结核菌株的贝达喹啉耐药风险。
临床怎么用
- 对广泛耐药结核患者,不应因耐药担忧而延迟或拒绝使用贝达喹啉。
- 应优先保障广泛耐药结核患者获得含贝达喹啉方案。
局限性
- 本文为个人观点,未提供原始研究数据或系统评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Global rollout of the new antituberculosis drug bedaquiline has been slow, in part reflecting concerns about spread of bedaquiline resistance. Acquired resistance to bedaquiline is especially likely in patients with extensively drug-resistant (XDR) tuberculosis. However, the very high mortality rates of patients with XDR not receiving bedaquiline, and promising cohort study results, suggest these patients also have greatest need for the drug. In this Personal View, we argue that resistance concerns should not forestall use of bedaquiline in patients with XDR tuberculosis. Our position in favour of increased access to bedaquiline for these patients is based on three arguments. First, the use of drug combinations that include bedaquiline might prevent spread of XDR disease to others in the community. Second, until new combination regimens of novel drugs for XDR tuberculosis become available, patients with XDR disease and their infected contacts will face equivalent outcomes if bedaquiline is either not provided because of policy, or not effective because of resistance. Finally, because resistance to bedaquiline and other antituberculosis drugs is caused by mutations within a single bacterial chromosome, use of bedaquiline in patients with XDR tuberculosis will not substantially increase the risk of bedaquiline resistance in patients with drug-susceptible or multidrug-resistant (non‑XDR) tuberculosis strains.
引用
- Kunkel A, Furin J, Cohen T, et al. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? Lancet Infect Dis. 2017. PMID: 28533094. doi:10.1016/S1473-3099(17)30299-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。